We reached out to investigators at Massachusetts General Hospital and asked them to give us one science-backed action people can take to improve their heart health.
Call the Department of Gastroenterology: 617-726-2426
Explore This Treatment
This year over 50,000 men and women in the U.S. will die from colon cancer. And many could have been saved. When colon cancer is detected early, there is a 90% survival rate. When it's not, that number is less than 50%. Starting at age 50, you should have a colonoscopy at least once every ten years to screen for polyps and cancer. Colon cancer can be beaten. Prevention and early detection are your best weapons.
We offer the most advanced colon cancer screenings and treatments available. Our world-renowned specialists can provide the comprehensive care and peace of mind you'll only find at one of the world's leading hospitals.
Talk to your doctor about scheduling your colorectal cancer screening at Massachusetts General Hospital. Then call (617) 726-2426 or request an appointment online.
Please visit our doctors page for a list of our gastroenterologists.
Other Options for Colorectal Cancer Screening
Understanding the different CRC screening options, including home-based stool tests and colonoscopy, depends on the individual risk of colon cancer and the patient’s preferences. Patients can explore and compare the benefits, harms, and risks of each option as they make an informed decision about what matters most to them.
The below sheet describes three screening options that are reasonable for most people: schedule a colonoscopy, have a stool-based test, or delay your colonoscopy for a year.
Colonoscopy Risks and Benefits
Related News and Articles
- Jan | 26 | 2024
Research Spotlight: Transportation Insecurity and Adverse Health Outcomes Among Adults with Chronic Liver Disease
In a nationally representative of US adults with self-reported chronic liver disease (CLD), approximately 308,000 (6%) identified delaying medical care due to transportation barriers.
- Jan | 24 | 2024
Research Spotlight: Tofacitinib Is Effective in Treating Refractory Immune Checkpoint Inhibitor Hepatitis
Michael Dougan, MD, PhD, is a senior author of a new study in Clinical Gastroenterology and Hepatology, Tofacitinib Is Effective in Treating Refractory Immune Checkpoint Inhibitor Hepatitis.
- Jan | 12 | 2024
In this 12-month, placebo-controlled, randomized clinical trial of 26 well-treated persons with HIV without known CVD, eplerenone was associated with a significant reduction in arterial inflammation.
- Press Release
- Dec | 20 | 2023
Blocking reductive stress in the liver may benefit people with conditions such as obesity and fatty liver disease.
- Oct | 20 | 2023
Arabs represent about 5% of the world population and are massively underrepresented in genomic studies worldwide, yet minimal efforts have been made to date to understand clinical utility of polygenic scores in this group.